ClinicalTrials.gg
RecruitingNCT02208869RuFHUpdated Nov 2, 2022

Russian Familial Hypercholesterolemia Registry

An observational study in Familial Hypercholesterolemia, sponsored by Russian Cardiology Research and Production Center. Recruiting at 5 sites in Russian Federation. Open to participants aged 7 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Russian Cardiology Research and Production Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
7 Years to 80 Years
Sex
All
01

Study summary

True prevalence of FH in the Russian Federation is unknown which leads to low percentage of diagnosed and treated cases. Research is needed to determine the prevalence of FH, specific diagnostic algorithms and optimal treatment strategies. The main aim of the present study is to evaluate the extent to which FH is underdiagnosed and undertreated in the Russian Federation for reduction of cardiovascular risk related to atherosclerosis in the country.

As a first step, total cholesterol (TC) and low-density lipoprotein (LDL-C) levels will be determined in a random sample from Moscow population (n=18000). It is expected that TC ≥ 7.5 mmol/L will be detected in 10% of cohort. During 2014, approximately 500 patients will pass through non-invasive clinical examination at the Russian Cardiology Research and Production Center, including patient demographics, past medical history, family history of hypercholesterolemia, physical findings, current lipid-lowering therapies, blood tests, genetic analysis, echocardiography, carotid duplex ultrasound and exercise SPECT imaging in selected cases. On the basis of the Moscow Program four major Federal Medical Centers will be involved, and FH Registry will be created as a national, multi-center initiative to screen FH patients, control their diagnosis and management, and track clinical-reported outcomes over time.

Establishment of National Guidelines for the diagnosis and treatment of FH on the basis of these data and implementation those into clinical practice in different regions of Russia will allow improving patient care. As an expected outcome, this program will raise awareness and increase appropriate assessment and treatment of FH patients in Russia, leading to a timely detection of the disease and therapy initiation.

Read the detailed description

*Design. We have chosen a randomly selected cohort of individuals who have been tested in the Moscow office of the "INVITRO" Laboratory on the basis of advertising campaign held in September, 2013, for the purpose of TC level measurement and determination of cardiovascular risk with the use of SCORE chart. The operator from the "INVITRO" Laboratory identified potential FH patients based on TC (≥7.5 mmol/L) or LDL-C (≥4.9 mmol/L) values.

Following identification, the potentially eligible participants suspected for FH are sent a notification letter describing the patient's high cholesterol level, at-atherosclerosis risk status and need for additional screening on the basis of the Russian Cardiology Research and Production Center. Those who give preliminary agreement for participation in the Program are invited to the Institution, where, after signing the ICF, they will undergo clinical (biochemical, echo, duplex scan) and genetic testing. Those individuals refusing to participate in the Program will be taken into account with fixing the reason of unwillingness to participate.

Patients under the age of 18 will be enrolled only with the explicit consent of a parent or legal guardian. All participants will be provided with the information about the Russian FH Community and Russian FH Registry.

All included subjects will be provided with a screening questionnaire querying the patient demographics, past medical history, patient FH history and diagnosis with FH type heterozygous or homozygous, family history of hypercholesterolemia, physical examination findings, current lipid-lowering therapies, and patients' contact information for further follow-up. After initialization of online data capture form (Electronic Medical System), the information will be also entered in the system. Blood and gene banks will be formed; analysis of echocardiography data for aortic valve stenosis, carotid duplex ultrasound for atherosclerosis burden, and exercise SPECT imaging in selected cases of suspected coronary heart disease (CHD) will be performed during the baseline visit. Patients diagnosed with FH on the basis of Dutch Lipid Clinic Network, Simon Broome Criteria and genetic testing will be provided information about screening of first-degree relatives, and additional educational materials about FH (under development).

To determine the true number of heterozygous forms among individuals with a probable diagnosis of FH molecular genetic testing is planned. When a causative mutation is found in the index case, a genetic test will be offered to all first-degree relatives.

Enrolled patients will be asked to update information at annually intervals. Since the last date of data entry, occurrence of major adverse cardiovascular events (acute coronary syndromes, stroke, myocardial revascularization, peripheral revascularization, cardiovascular death), changes in medications, hospitalizations to any reasons, genetic testing, laboratory values, and all-cause mortality will be reviewed.

Follow-up data will be collected yearly following initial enrollment. Updated information on quality of life will be collected. Annual reminder emails will be sent to all patients to call the following physician.

We estimate that at one site during one year (2014-2015) we will screen 500 patients eligible for the participation from the potentially eligible 1505 selected from 18000 individuals.

  • Five leading Federal Medical Centers in different regions of Russia will be involved at the first two steps of the Program:

    1. Federal State Institution "Russian Cardiology Research and Production Center" of the Health Ministry of the Russian Federation (Moscow); First line Federal Medical Centers
    2. Samara State Medical University (Samara);
    3. Research Institute of Internal Medicine (Novosibirsk);
    4. Saint-Petersburg State University (Sokolov Center for atherosclerosis and lipid disorders in Clinical Hospital №122 (Saint Petersburg));
    5. Chelyabinsk State Medical Academy (Chelyabinsk)
  • A total of three scheduled visits are planned during the course of this study. Visit 1 will occur during the Screening Period (Part A). Patients who enter the Screening Period (Part A) will be signing the ICF, instructed to follow regional dietary guidelines for the duration of the study. They will undergo clinical (biochemical, ultra-sound, duplex scan) and exercise SPECT imaging if applicable. Those individuals refusing to participate in the study will be taken into account with fixing the reason of unwillingness to participate.

All included subjects will be provided with a screening questionnaire querying the patient demographics, past medical history, patient FH history and diagnosis with FH type heterozygous or homozygous, family history of hypercholesterolemia, physical examination findings, current lipid-lowering therapies, and patients' contact information for further follow-up. After initialization of online data capture form (Electronic Medical System), the information will be also entered in the system.

For the patients with FH diagnosed on the basis of Dutch Lipid Clinic Network and/or Simon Broome Criteria or genetic testing Visit 2 will occur in a one month period. Visit 3 will occur in RussianCRPC in a one year±10 days period. At the scheduled visits update of the medical information, including monitoring of adverse cardiovascular events occurrence, changes in medications, and blood sampling, will be performed.

  • Examination procedures at the scheduled visits:

    1. Signing the informed consent form (ICF)
    2. Filling the questionnaires to determine the classical cardiovascular risk factors, past medical history and treatment
    3. Applying Dutch Lipid Clinic Network (DLCN) and Simon Broome Register (SBR) criteria
    4. Maintaining Electronic Medical System by physicians participating in the Program
    5. Blood sampling for TC, triglycerides (TG), LDL-C, HDL-C, Lp(a), high-sensitivity C-reactive protein (hsCRP), PCSK9 measurement
    6. Genetic testing (mutations in the LDLR, apolipoprotein B (apoB), PCSK9 genes)
    7. Echocardiography for the assessment of ascending aorta and aortic valve
    8. Duplex scanning of the carotid arteries for the assessment of intima-media thickness and plaques' characteristics
    9. Exercise SPECT imaging in patients suspicious for coronary disease
    10. Annual evaluation of cardiovascular events (myocardial infarction, stroke, cardiovascular death, non-cardiovascular death, hospitalization due to acute coronary syndrome, heart failure, arterial revascularization procedures (percutaneous coronary intervention, coronary artery bypass grafting, endovascular or surgical revascularization in carotid arteries or lower extremities), aortic valve replacement.
  • FH patients at these 1-st line Sites who meet inclusion criteria as described in the Methods section will be eligible to enroll. The same algorithm as described above will be initiated. Specialized staff from the Russian Cardiology Research and Production Complex (as a Core Center) will monitor the effectiveness and credibility of the undertaken work. Filling in the Electronic Medical System (eCRF) will be checked by the staff from the Core Center, and each year teleconferences will be held between the Sites-Participants of the Program.
  • Perspectives: since 2018 ¬ the next phases of the Program will include recruitment of new set of Clinics, Policlinics and Institutions across Russia with specialized lipid clinics that could demonstrate acceptable feasibility for patient enrollment and engagement.
02

Conditions studied

  • Familial Hypercholesterolemia

Keywords

  • familial hypercholesterolemia
  • cholesterol
  • prevention
  • registry
  • atherosclerosis
  • treatment
  • prevalence
03

In context

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 770 across 64 observational studies indexed under Hyperlipoproteinemia Type II.

Browse Hyperlipoproteinemia Type II studies →

Lead sponsor

Russian Cardiology Research and Production Center is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Russian cohort of individuals who have been tested in the offices of the "INVITRO" Laboratory on the basis of advertising campaign for the purpose of total cholesterol level measurement and determination of cardiovascular risk with the use of SCORE chart.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Total cholesterol ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L (pretreatment levels)
  • Familial hypercholesterolemia defined as: a. Mutation in the LDL receptor and/or the ApoB gene and/or the PCSK9 gene; or b. clinical diagnosis of heterozygous FH (HeFH) according to the Dutch Lipid Network Criteria or Simon Broom Criteria
  • Patients with genetic mutation of FH

Exclusion criteria

Exclusion Criteria:

  • uncontrolled primary hypothyroidism (thyroid stimulating hormone (TSH) >1.5 x (ULN)),
  • nephrotic syndrome and/or renal dysfunction (scrum creatinine >2.0 mg/dL or 160mmol/l, \<15 ml/min) at screening.
  • uncontrolled diabetes mellitus ( >8.5%)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients diagnosed with FH

    Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria. Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c \>8%) or hypothyroidism (thyroid-stimulating hormone \>1.5 upper normal limit), renal failure (creatinine clearance \<30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study.

06

What researchers measure

Primary outcomes

  1. Prevalence of FH patients in the Russian Federation

    Time frame: at baseline

Secondary outcomes

  1. Number of patients with heterozygous and homozygous forms of FH in Russia

    Time frame: at baseline

  2. Distribution of lipoprotein(a) in individuals diagnosed with definite and probable FH.

    Time frame: at baseline

  3. Severity of carotid atherosclerosis, aortic valve stenosis and coronary heart disease in Russian patients with FH

    Assessment of carotid atherosclerosis will be performed with the use of carotid duplex scanning. Presence and severity of aortic valve stenosis will be evaluated with echocardiography. Exercise radionuclide myocardial perfusion imaging with single-photon emission computed tomography (SPECT) will be used for the diagnosis of myocardial ischemia in patients suspicious for CHD.

    Time frame: at baseline

  4. Mutations in following genes: low-density lipoprotein receptor (LDLR), proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein B (apoB)

    Genetic testing for FH-causing mutation in patients with probable and definite FH

    Time frame: At baseline

  5. Russian Registry of individuals with FH

    Contribution in the formation of the Russian Health Ministry legislative acts concerning significance of FH as a socially and medically important disease with appropriate management strategies.

    Time frame: up to 10 years

  6. Prognosis of individuals with FH

    Incidence of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization procedures (cardiac, carotid, or peripheral), hospitalizations due to unstable angina pectoris or heart failure, all-cause mortality, diabetes in participants without baseline diabetes, new or recurrent cancers.

    Time frame: at 1, 3, 5, 10 years

Other outcomes

  1. Clinical and diagnostic significance of Dutch Lipid Clinic Network criteria and Simon Broome Registry criteria for diagnosis of FH in Russian population

    Clinical and diagnostic significance of Dutch Lipid Clinic Network criteria and Simon Broome Registry criteria for the diagnosis of FH in Russia.

    Time frame: up to 5 years

  2. Family Health Team model and cascade testing in individuals with FH

    Time frame: up to 3 years

07

Study locations

1 of 5 sites recruiting
  • Chelyabinsk State Medical Academy
    Chelyabinsk, 454092, Russian Federation
    Not yet recruiting
    • Igor Shaposhnik, MD, DMSc · Contactshaposhnik@yandex.ru · +79088235120
    • Bogdanov Dmitriy, MD, PhD · Contactdmitrchel@mail.com.ru · +79124773437
    • Igor Shaposhnik, MD, DMSc · Principal investigator
    • Bogdanov Dmitriy, MD, PhD · Sub investigator
    • Salashenko Aleksey, MD< PhD · Sub investigator
    • Genkel Vadim, MD, PhD · Sub investigator
  • EI Chazov National Medical Research Center of Cardiology
    Moscow, 121552, Russian Federation
    Recruiting
    • Marat Ezhov, MD, PhD · ContactMarat_Ezhov@mail.ru · +791041374993558
    • Igor Sergienko, MD, PhD · Contactigorcardio@mail.ru · +79031492253
    • Vladmir Malakhov, MD,PhD · Sub investigator
    • Diana Nozadze, MD,PhD · Sub investigator
    • Natalya Gornyakova, MD,PhD · Sub investigator
    • Alexey Ansheles, PhD · Sub investigator
    • Tatiana Balakhonova, MD, DMSc · Sub investigator
    • Olga Pogorelova, PhD · Sub investigator
    • Maria Tripoten, PhD · Sub investigator
    • Grigory Heymets, PhD, DSc · Sub investigator
    • Narek Tmoyan, MD · Sub investigator
    • Ulyana Chubykina, MD · Sub investigator
    • Svetlana Bliznyuk, MD · Sub investigator
    • Tatyana Rozhkova, MD · Sub investigator
  • Novosibirsk Research Institute of Internal Medicine, Institute of Internal Medicine Siberian Branch of the Russian Academy of Medical Sciences
    Novosibirsk, 630089, Russian Federation
    Not yet recruiting
    • Mikhail Voevoda, MD, DMSc · Contactmvoevoda@ya.ru · +79139505088
    • Yulia Ragino, MD, DMSc · Contactragino@mail.ru · +79537799704
    • Mikhail Voevoda, MD, DMSc · Principal investigator
    • Yulia Ragino, MD, DMSc · Sub investigator
    • Elena Shakhtshneider, MD, DMSc · Sub investigator
    • Ksenia Makarenkova, MD, PhD · Sub investigator
    • Elena Antonova, MD, PhD · Sub investigator
    • Elena Voevoda, MD · Sub investigator
  • Saint-Petersburg State University and North-West State Medical University n.a. I.I.Mechnikov
    Saint Petersburg, Russian Federation
    Not yet recruiting
    • Viktor Gurevich, MD, DMSc · Contactvktrgurevich@gmail.com · +78125599759
    • Soreya Urazgildeeva, MD, DMSc · Contactdocsau64@yandex.ru · +78125599759
    • Viktor Gurevich, MD, DMSc · Principal investigator
    • Soreya Urazgildeeva, MD, DMSc · Sub investigator
    • Alexey Tregubov, MD, PhD · Sub investigator
    • Maria Muzalevskaya, MD, PhD · Sub investigator
  • Samara State Medical University
    Samara, 443099, Russian Federation
    Not yet recruiting
    • Mikhail Kachkovsky, MD, PhD · Contactkma10@yandex.ru · +79171187181
    • Olesya Rubanenko, MD, PhD · Contactolesya.rubanenko@gmail.com · +79371887780
    • Mikhail Kachkovsky, MD, DMSc · Principal investigator
    • Olesya Rubanenko, MD, PhD · Sub investigator
    • Dmitry Duplyakov, MD, DMSc · Principal investigator
08

References and documents

Publications

  • M. S. Safarova, I. V. Sergienko, M. V. Ezhov, A. E. Semenova, M. A. Kachkovskiy, I. I. Shaposhnik, V. S. Gurevich, M. I. Voevoda, Y. P. Nikitin, V. V. Kuharchuk, Yu. A. Karpov Russian research program for early diagnosis and treatment of familial hypercholesterolaemia: Rationale and Design of the Russian FH Registry (RuFH). Journal of ATHEROSCLEROSIS AND DYSLIPIDAEMIAS 3: 7-15, 2014 (in Russian)
  • Ezhov MV SI, Duplyakov DV, Abashina OE, Kachkovsky MA, Shaposhnik II, Genkel VV, Gurevich VS, Urazgildeeva SA, Tregubov AV, Konovalova TB, Muzalevskaya MV, Voevoda MI, Bazhan SS, Makarenkova KV, Timoshenko OV, Ragino YI, Urvantseva IA, Cozhocar KG, Sokolov AA, Boeva OI, Bolotova EV, Kushnaryova YB, Kuznetsova TY, Korneva VA, Bogdanov DY, Chichina EE, Soloviev VM, Smolenskaya OG, Galyavich AS, Safarova MS, Popova AV, Malakhov VV, Ansheles AA, Nozadze DN, Semenova AE, Rozhkova TA, Solovéva EY, Gornyakova NB, Karpov YA, Kukharchuk VV. Results of the Russian research program on the diagnosis and treatment of patients with familial hypercholesterolemia. High prevalence, low awareness, poor adherence. Atherosclerosis and Dyslipidaemias An official Journal of the Russian National Atherosclerosis Society (RNAS) 2017;2:5-15.
  • EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Freiberger T, Abifadel M, Aguilar-Salinas CA, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Ceska R, Corral P, Descamps O, Dieplinger H, Do CT, Durst R, Ezhov MV, Fras Z, Gaita D, Gaspar IM, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam CS, Latkovskis G, Laufs U, Liberopoulos E, Lin J, Lin N, Maher V, Majano N, Marais AD, März W, Mirrakhimov E, Miserez AR, Mitchenko O, Nawawi H, Nilsson L, Nordestgaard BG, Paragh G, Petrulioniene Z, Pojskic B, Reiner Ž, Sahebkar A, Santos LE, Schunkert H, Shehab A, Slimane MN, Stoll M, Su TC, Susekov A, Tilney M, Tomlinson B, Tselepis AD, Vohnout B, Widén E, Yamashita S, Catapano AL, Ray KK. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl. 2016;22:1-32. doi: 10.1016/j.atherosclerosissup.2016.10.001.
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Dec 2017 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2014
First posted
Aug 5, 2014
Start
Jan 2014
Primary completionActual
Dec 31, 2017
CompletionEst.
Dec 31, 2026
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02208869
Lead sponsor
Russian Cardiology Research and Production Center
Collaborators
Pfizer, Amgen, AstraZeneca
Responsible party
Marat Vladislavovich Ezhov (MV Ezhov, MD, PhD, DMSc) (Leading Researcher, MD, DMSc, Russian Cardiology Research and Production Center) — Principal investigator
First posted
Aug 5, 2014
Start date
Jan 2014
Primary completion
Dec 31, 2017
Completion
Dec 31, 2026 (estimated)
Last update
Nov 2, 2022

Study contacts

Marat Ezhov, MD, PhD
Contact
Marat_Ezhov@mail.ru
+79104137499
Igor Sergienko, MD, DMSc
Contact
igorcardio@mail.ru
+79031492253
Valery Kukharchuk, MD, DMSc
study chair · Russian Cardiology Research and Production Center
Igor Sergienko, MD, DMSc
study director · Russian Cardiology Research and Production Center
Marat Ezhov, MD, DMSc
principal investigator · Russian Cardiology Research and Production Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion